ATOS Archives - BioTuesdays

Markets

Rodman & Renshaw starts Atossa at buy; PT $12

Rodman & Renshaw initiated coverage of Atossa Therapeutics (NASDAQ: ATOS) with a “buy” rating and price target of $12.00. The stock closed at $2.28 on July 6. Atossa, a clinical-stage biopharmaceutical company...

July 7, 2026

Developments

USPTO grants Atossa patents strengthening breast cancer treatment portfolio

Atossa Therapeutics (NASDAQ:ATOS) announced that the USPTO has granted a new patent for enteric oral formulations comprising (Z)-endoxifen, including methods of treating patients. According to Atossa, the patent...

April 22, 2025

Developments

Atossa announces plan to pursue MBC indication for (Z)-endoxifen

Atossa Therapeutics (NASDAQ:ATOS) announced its decision to pursue a metastatic breast cancer (MBC) indication for (Z)-endoxifen. According to Attosa, it also plans to work with the FDA to advance additional...

March 11, 2025

Developments

Atossa, Quantum Leap in new study arm of I-SPY 2 clinical trial

Atossa Therapeutics (NASDAQ:ATOS) and Quantum Leap Healthcare Collaborative announced that Atossa’s proprietary selective estrogen receptor modulator, (Z)-endoxifen, will be evaluated in a new study arm of the ongoing I...

March 22, 2023

Developments

Atossa doses first patient in Phase 2 breast cancer study

Atossa Therapeutics (NASDAQ:ATOS) dosed the first patient in the Phase 2 EVANGELINE non-inferiority clinical trial of Atossa’s patented selective estrogen receptor modulator, (Z)-endoxifen, and exemestane plus goserelin...

February 23, 2023

Developments

Atossa to acquire stake in Dynamic Cell Therapies

Atossa Therapeutics (NASDAQ:ATOS) is acquiring 19.99% of the capital stock of closely-held Dynamic Cell Therapies for $2-million, in addition to $3-million previously paid to Dynamic, “This investment in Dynamic...

November 1, 2022

Feature

Atossa Therapeutics pivots inhalation therapy from COVID-19 to oncology

With widespread availability of SARS-CoV-2 vaccines and other therapies now approved to treat COVID-19, Atossa Therapeutics (NASDAQ:ATOS) has pivoted development of its AT-H201 inhalation therapy to cancer patients with...

October 25, 2022

Tag - ATOS

Rodman & Renshaw starts Atossa at buy; PT $12

USPTO grants Atossa patents strengthening breast cancer treatment portfolio

Atossa announces plan to pursue MBC indication for (Z)-endoxifen

Atossa, Quantum Leap in new study arm of I-SPY 2 clinical trial

Atossa doses first patient in Phase 2 breast cancer study

Atossa to acquire stake in Dynamic Cell Therapies

Atossa Therapeutics pivots inhalation therapy from COVID-19 to oncology

Subscribe